阿狄科®非对称二甲基精氨酸检测试剂盒（酶联免疫法）

【产品名称】
通用名称：阿狄科®非对称二甲基精氨酸检测试剂盒（酶联免疫法）

【预期用途】
适用于人血清、柠檬酸盐和 EDTA 血浆中不对称二甲基-L-精氨酸的定量测定。仅供科研使用。

【包装规格】
规格：96人份（复孔检测样本：40个）/盒
测试次数：96（40份样本一式两份）

【背景知识】
不对称二甲基L-精氨酸是NO合酶的内源性抑制剂。它是在甲基化蛋白质分解过程中形成的，可通过肾脏消除或通过二甲基精氨酸二甲基氨基水解酶代谢。各种细胞类型，包括人类内皮细胞和肾小管细胞，产生和代谢不对称二甲基L-精氨酸。在许多与内皮功能障碍相关的疾病中，不对称二甲基L-精氨酸 的血液水平升高。在患有高胆固醇血症、高血压、动脉硬化、慢性肾功能不全的患者中已经证明 不对称二甲基L-精氨酸浓度升高和慢性心功能不全，并与受限的内皮依赖性血管舒张有关。
近年来，NO对血管张力和结构的调节具有重要的临床意义。据报道，人内皮细胞除NO外还产生不对称二甲基L-精氨酸，这表明内源性NO调节是通过内皮中的不对称二甲基L-精氨酸，因此推测肾功能不全患者高血压、动脉硬化和免疫功能障碍的多发与L-精氨酸/NO代谢受损和不对称二甲基L-精氨酸的蓄积密切相关。迄今为止，导致L-精氨酸-NO代谢变化的机制仅部分阐明。当然，这是一个多因素的现象，i.a.自由基增加，不对称二甲基L-精氨酸积累和NO合酶活性降低。
近年来的前瞻性研究使不对称二甲基L-精氨酸作为一种新的心血管风险标志物或因素变得越来越重要。

适应症：

参考文献：
1.Boger RH, Bode-Boger SM, Szuba A, Tangphao O, Tsao PS, Chan JR, Blaschke TF,Cooke JP. Asymmetric dimethylarginine: a novel risk factor for endothelialdysfunction.Its role in hypercholesterolemia.Circulation 1998;98: 1842-1847
2.Boger RH. The emerging role of asymmetric dimethylarginine as a novelcardiovascular risk factor.Cardiovasc Res. 2003;59: 824-833
3.Kielstein JT,Boger RH,Bode-Boger SM,et al. Asymmetric dimethylarginineplasma concentrations differ in patients with end-stage renal disease:Relationship to treatment method and atherosclerotic disease.JAm SocNephrol.1999; 10:594-600
4.Lu TM，Ding YA,Lin SJ,Lee WS,Tai HC. Plasma levels of asymmetricaldimethylarginine and adverse cardiovascular events after percutaneous coronaryintervention.Eur Heart J.2003;24: 1912-1919.
5.Nijveldt RJ,Teerlink T,Van der Hoven B, Siroen MP,Kuik DJ, Rauwerda JA, vanLeeuwen PA.Asymmetrical dimethylarginine in critically ill patients: highplasma Asymmetric dimethylarginine concentration is an independent risk factor of lCU mortality.ClinNutr. 2003;22: 23-30
6.Savvidou MD,Hingorani AD,Tsikas D, Frolich JC,Vallance P,Nicolaides KH.Endothelial dysfunction and raised plasma concentrations of asymmetricdimethylarginine in pregnant women who subsequently develop pre-eclampsia.Lancet 2003;361: 1511-1517
7.Stuhlinger M,Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, ReavenGM, Tsao PS.Relationship between insulin resistance and an endogenous nitricoxide synthase inhibitor.JAm Med Assoc. 2002;287:1420-1426
8.Vallance P,Leone A,Calver A,Collier J,Moncada S. Accumulation of anendogenous inhibitor of NO synthesis in chronic renal failure.Lancet 1992;339:572-575
9.Zoccali C, Bode-Boger SM,Mallamaci F, Benedetto FA,Tripepi G,Malatino L,Cataliotti A, Bellanuova l, Fermo l,Frolich JC, Boger RH. Asymmetric dimethylarginine: An endogenous inhibitor of nitric oxide synthasepredicts mortality in end-stage renal disease(ESRD).Lancet 2001;358:2113-2117
10.Aktoz T,Aktoz M, TatlnE,Kaplan M,Turan FN, Barutcu A, Atakan lH, Demir M,AltunA.Assessment of the Relationship between Asymmetric Dimethylarginine and Severity of Erectile Dysfunction and Coronary Artery Disease. Int Urol Nephrol.Dec; 42(4):873-9.doi: 10.1007/s11255-009-9696-9
11.Ayer JG, HarmerJA, Xuan W, Toelle B, Webb K, Almqvist C, Marks GB, Celermajer Ds.Dietary Supplementation with N-3 Polyunsaturated Fatty Acids in EarlyChildhood: Effects on Blood Pressure and Arterial Structure and Function at Age8 Y.Am JClin Nutr.2009 Aug; 90(2):438-46. doi: 10.3945/ajcn.2009.27811
12.Bang OY, Chung J, Kim SJ, Chung Jet al.Caveolin-1，Ring finger protein 213, and endothelial function in Moyamoya disease. Int J Stroke. 2016;0(0):1-10.doi:10.1177/1747493016662039
13.Brenner T, Fleming TH, Rosenhagen C Krauser U, Mieth M, Bruckner T, Martin E,Nawroth PP,Weigand MA,Bierhaus A, Hofer S. L-arginine and asymmetricdimethylarginine are early predictors for survival in septic patients with acuteliver failure.Mediators Inflamm. 2012:210454.doi:10.1155/2012/210454.
14.Celik M, Cerrah S, Arabul M Akalin A.Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabeticpatients. J Diabetes Res.2014: 139215
15.KurtogluE, Balta S, Sincer l, Altas Y,Atas H, Yilmaz M, Korkmaz H, Erdem K,Akturk E, Demirkol S, Can C.Comparision of Effects of Rosuvastatin versus AtorvastatinTreatment on Plasma Levels of Asymmetric Dimethylarginine in Patients withHyperlipidemia Having Coronary Artery Disease.Angiology. 2014 65(9);:788-93.doi:10.1177/0003319713507333
16.Sandoo A, Dimitroulas T, Hodson J, Smith JP, Douglas KM, Kitas GD.Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoidarthritis: a 6 year follow-up study. Rheumatology (Oxford, England).2014;(September 2014):1-8.doi:10.1093/rheumatology/keu349